Wire · operational-macro
Fierce Pharma Asia—Lilly's $3.35B InnoCare deal; Korea's breakthrough; China's 5-year ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
Eli Lilly and China's InnoCare Pharma launched a $3.35 billion drug discovery deal; FDA approved the first novel cancer drug from Korea's Elevar Therapeutics; China unveiled an ambitious pharmaceutical five-year plan targeting a 25% global share of first-in-class drugs by 2030.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 24 Sep 2026 and 25 Sep 2026.
◆ ◆ The Wire takeaway
Asia-Pacific biotech investment just surged with multi-billion dollar deals and FDA approvals signaling increased market openness and competitive pressure; you in pharma or biotech should engage regional partners now to secure a footprint before this market rapidly consolidates.
◆ Coverage
3 sources · first reported 24 Sep 2026 · latest 25 Sep 2026
◆ Related on Wire
◆ Topics